ClinicalTrials.gg
RecruitingNCT06096116Updated Sep 28, 2026

Phase 3 Study on the Efficacy and Safety of Human Plasma Derived Antithrombin (Atenativ) in Heparin-Resistant Patients Scheduled to Undergo Cardiac Surgery Necessitating Cardiopulmonary Bypass

A Phase 3 interventional study of Human plasma derived antithrombin and Placebo in Acquired Antithrombin Deficiency, sponsored by Octapharma. Recruiting at 27 sites in 10 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-09-28.

Sponsored by Octapharma · Phase 3, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Aug 2024; still recruiting 2 years 3 months later.
Updated Sep 28, 2026Site recruiting status changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

The primary objective of this study is to evaluate the efficacy of two different doses of Atenativ, versus placebo, in restoring and maintaining heparin responsiveness in adult patients undergoing cardiac surgery necessitating cardiopulmonary bypass (CPB)

02

Conditions studied

  • Acquired Antithrombin Deficiency

Keywords

  • heparin resistance
  • antithrombin deficiency
  • cardiopulmonary bypass
  • cardiac surgery
03

In context

Lead sponsor

Octapharma is the lead sponsor of 71 studies on the registry; 8 are open to participants now.

Of its 17 completed or terminated interventional studies of FDA-regulated products, 16 (94%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Planned cardiac surgery with CPB
  2. Heparin-resistant patients (pre-CPB Hemochron ACT less than 480 s in the measurement taken between 2-5 minutes following intravenous administration of 500 U/kg UFH)
  3. Patients between 18 and 85 years of age, inclusive
  4. Freely given written or electronic
  5. In female patients of , a pre-existing negative pregnancy test within 14 days prior to surgery

Exclusion criteria

Exclusion Criteria:

  1. Receiving, or have received within the timeframes specified, one or more of the following medications prior to the start of surgery:

    1. vitamin K antagonists (within 3 days)
    2. direct oral anticoagulants (within 2 days)
    3. thienopyridines (ticlopidine within 14 days, prasugrel within 7 days, or clopidogrel within 5 days), unless function is satisfactory according to local standard of care assessment
    4. ticagrelor (within 5 days), unless platelet function is satisfactory according to local standard of care assessment
    5. glycoprotein IIb/IIIa antagonist (within 24 hours)
  2. Pre-existing coagulopathy, a history of bleeding problems, or a laboratory-diagnosed bleeding disorder (e.g., von Willebrand disease, platelet disorder)
  3. Renal insufficiency, defined as serum creatinine level >2.0 mg/dL
  4. Thrombocytosis, defined as platelet count >400,000 per μL
  5. Known or allergic reaction to antithrombin or any of the in Atenativ, i.e., human albumin, sodium chloride, acetyl tryptophan, caprylic acid
  6. History of anaphylactic reaction(s) to blood or blood components
  7. Refusal to receive transfusion of blood or blood-derived products
  8. Current participation in another interventional clinical trial or previous participation in the current trial
  9. Treatment with any IMP within 30 days prior to screening visit
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    Low-dose Atenativ

    Patients will receive a single bolus of 30 international units (IU)/kg body weight (BW) Atenativ.

    Drug: Human plasma derived antithrombin

  • Experimental
    High-dose Atenativ

    Patients will receive a single bolus of 60 international units (IU)/kg body weight (BW) Atenativ.

    Drug: Human plasma derived antithrombin

  • Placebo comparator
    Placebo

    Patients will receive a saline bolus dose

    Drug: Placebo

Interventions

  • DrugHuman plasma derived antithrombin

    A solvent/detergent and heat-treated antithrombin concentrate derived from human plasma

  • DrugPlacebo

    Half of the patients in the placebo group will be randomised to receive a volume of placebo corresponding to the low dose of Atenativ and the other half to receive a volume of placebo corresponding to a high dose of Atenativ

06

What researchers measure

Primary outcomes

  1. Restoring heparin responsiveness

    The percentage of patients in each group in whom no further therapy containing antithrombin (i.e. frozen plasma or other antithrombin concentrates) is needed for restoring pre-CPB heparin responsiveness after administration of Atenativ or placebo, and for maintaining it during CPB

    Time frame: During surgery (from the time of the first surgical incision to the time at which the final suture or staple is placed)

Secondary outcomes

  1. Amounts of further therapy for restoring heparin responsiveness

    The comparison between the amounts of further therapy containing antithrombin (i.e., FP or antithrombin concentrates) needed for restoring pre-CPB heparin responsiveness, after administration of Atenativ or placebo, and for maintaining it during CPB

    Time frame: During surgery (from the time of the first surgical incision to the time at which the final suture or staple is placed)

  2. Change in activated clotting time (ACT) values

    The comparison between the change in ACT values following infusion of each of the Atenativ doses and placebo

    Time frame: Within 5 minutes following intravenous administration of 500 U/kg unfractionated heparin (UFH) and between 2-10 minutes after IMP infusion

  3. Change in antithrombin plasma levels

    The comparison between the change in antithrombin plasma levels following infusion of each of the Atenativ doses and placebo

    Time frame: Within 10 minutes before IMP infusion and between 2 and 10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after the start of IMP infusion

  4. Change in heparin usage

    The comparison between heparin usage following the infusion of each of the Atenativ doses and infusion of placebo

    Time frame: From end of IMP infusion to the end of surgery

  5. FP unit use

    The comparison between the number of units of FP transfused for reasons other than restoring or maintaining heparin responsiveness, both intraoperatively (from the start of Atenativ or placebo infusion until the start of CPB, during CPB, and from the end of CPB until the end of surgery) and postoperatively (from the end of surgery until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first), as well as cumulatively

    Time frame: From the start of IMP infusion until 24 hours following IMP infusion, and until discharge or 7 days after surgery, whichever comes first

  6. Amounts of further antithrombin concentrate for maintaining heparin responsiveness

    The comparison between postoperative use of antithrombin concentrates for reasons other than restoring heparin responsiveness (from the end of surgery until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first)

    Time frame: From placement of the final suture or staple until 24 hours following IMP infusion, to discharge or 7 days after surgery, whichever comes first

  7. Transfusion of allogenic blood products

    The comparison between transfusion of other allogeneic blood products (e.g., red blood cells \[RBCs\], platelets, cryoprecipitate, whole blood, albumin, other transfusion), both intraoperatively (from the start of Atenativ or placebo infusion until the start of CPB, during CPB, and from the end of CPB until the end of surgery) and postoperatively (from the end of surgery until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first), as well as cumulatively

    Time frame: From the start of IMP infusion until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first

  8. Administration of coagulation factor concentrates

    The comparison between administration of coagulation factor concentrates (fibrinogen concentrate, factor XIII concentrate, recombinant activated factor VII, other therapy)", both intraoperatively (from the start of Atenativ or placebo infusion until the start of CPB, during CPB, and from the end of CPB until the end of surgery) and postoperatively (from the end of surgery until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first), as well as cumulatively

    Time frame: From the start of IMP infusion until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first

  9. Administration of other haemostatic-relevant therapies

    The comparison between administration of other haemostatic-relevant therapies (i.e., tranexamic acid, aminocaproic acid, protamine, other therapies), both intraoperatively (from the start of Atenativ or placebo infusion until the start of CPB, during CPB, and from the end of CPB until the end of surgery) and postoperatively (from the end of surgery until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first), as well as cumulatively

    Time frame: From the start of IMP infusion until 24 hours after the start of Atenativ or placebo infusion and until discharge or 7 days after surgery, whichever comes first

  10. Postoperative chest tube drainage

    The comparison between postoperative chest tube drainage volume at 24 hours after the start of Atenativ or placebo infusion, and the comparison between total chest tube drainage volume until discharge or 7 days after surgery, whichever comes first

    Time frame: From the start of IMP infusion to 24 hours after infusion and until discharge or 7 days after surgery, whichever comes first

  11. Need for reoperation due to bleeding

    Comparison of the need for reoperation for bleeding, including description of the cause of bleeding (surgical vs. non-surgical)

    Time frame: 24 hours after the start of IMP infusion

  12. Cell saver volume

    The comparison between cell saver volume until the end of surgery

    Time frame: During surgery (from the time of the first surgical incision to the time at which the final suture or staple is placed)

  13. Adverse events

    Incidence of adverse events, including all related and non-related, non-serious adverse events

    Time frame: From the start of IMP infusion until hospital discharge or 7 days after IMP administration, whichever comes first

  14. Serious adverse events

    Incidence of serious adverse events

    Time frame: From the start of IMP infusion until 28 days after IMP administration

  15. Survival status

    Number of patients surviving in all three cohorts

    Time frame: At hospital discharge or 7 days after IMP administration (whichever comes first) and at 28 days (+ 4 days) after IMP administration

  16. Red Blood Cell count

    Standard haematological parameter

    Time frame: Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after infusion

  17. White Blood Cell count

    Standard haematological parameter

    Time frame: Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after infusion

  18. Haemoglobin levels

    Standard haematological parameter

    Time frame: Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after the end of CPB, at the end of surgery, and at 24 hours after infusion

  19. Haematocrit

    Standard haematological parameter

    Time frame: Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after weaning from CPB, at the end of surgery, and at 24 hours after infusion

  20. Platelet count

    Standard haematological parameter

    Time frame: Within 10 minutes before IMP infusion, between 2-10 minutes after IMP infusion, within 10 minutes after weaning from CPB, at the end of surgery, and at 24 hours after infusion

07

Study locations

22 of 27 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Aug 2024 (actual). Primary completion is estimated for Mar 2028, 43 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 17, 2023
First posted
Oct 23, 2023
StartActual
Aug 21, 2024
Primary completionEst.
Mar 2028
CompletionEst.
Mar 2028
Last update
Sep 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
5 sites changed recruiting status (2 now recruiting, 2 now terminated, …)
Show 5 sites
  • Cleveland Clinic · Cleveland, United StatesNot yet recruiting→Recruiting
  • Toronto General Hospital · Toronto, CanadaRecruiting→Not yet recruiting
  • Institute for Clinical and Experimental Medicine · Prague, CzechiaRecruiting→Terminated
  • Hospital of Lithuanian university of Health sciences Kauno Klinikos · Kaunas, LithuaniaRecruiting→Terminated
  • Institute of Cardiovascular Diseases Vojvodina · Kamenitz, SerbiaNot yet recruiting→Recruiting
Sep 28, 2026
Show all 1 update
  1. Sep 28, 2026
    5 sites changed recruiting status (2 now recruiting, 2 now terminated, …)
    Show 5 sites
    • Cleveland Clinic · Cleveland, United StatesNot yet recruiting→Recruiting
    • Toronto General Hospital · Toronto, CanadaRecruiting→Not yet recruiting
    • Institute for Clinical and Experimental Medicine · Prague, CzechiaRecruiting→Terminated
    • Hospital of Lithuanian university of Health sciences Kauno Klinikos · Kaunas, LithuaniaRecruiting→Terminated
    • Institute of Cardiovascular Diseases Vojvodina · Kamenitz, SerbiaNot yet recruiting→Recruiting
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06096116
Lead sponsor
Octapharma
Responsible party
Sponsor
First posted
Oct 23, 2023
Start date
Aug 21, 2024
Primary completion
Mar 2028 (estimated)
Completion
Mar 2028 (estimated)
Last update
Sep 28, 2026

Study contacts

Cristina Solomon, MD
Contact
Cristina.Solomon@octapharma.com
+41 79 585 90 42

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion